This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous integrated boost for prostate cancer.
Pathologically confirmed adenocarcinoma of prostate
Stage cT1-3N0M0 localized prostate cancer
performed PSMA PET/CT and mpMRI before treatment
No lymph nodes or distant metastasis
No pathologically confirmed adenocarcinoma of the prostate
Pelvic lymph node metastasis (N1)
Distant metastasis (M1)
Previous pelvic radiotherapy